VistaGen Therapeutics
VTGN
74 hedge funds and large institutions have $227M invested in VistaGen Therapeutics in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 28 increasing their positions, 5 reducing their positions, and 10 closing their positions.
460% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 5
220% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 10
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
78% more capital invested
Capital invested by funds: $127M → $227M (+$99.2M)
42% more funds holding
Funds holding: 52 → 74 (+22)
0.83% more ownership
Funds ownership: 1.63% → 2.46% (+0.83%)
Top Buyers
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$15.4M |
| 2 |
VA
VR Adviser
New York
|
+$15.4M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$10.7M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$10.3M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$6.29M |
Top Sellers
| 1 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$4.34M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.56M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$2.83M |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.88M |
| 5 |
Renaissance Technologies
New York
|
-$1.62M |
VTGN Hedge Fund Activity: Q1 2021 in Review
74 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2021, worth a combined $227M — up 78% from $127M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new VTGN positions and 10 closed out — a net gain of 22 holders — while 28 added to existing stakes and 5 trimmed.
The largest buyer was NEA Management Company, adding an estimated $15.4M. The largest seller was Asymmetry Capital Management, exiting entirely with an estimated $4.34M sold.
- 74 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2021, up from 52 in Q4 2020.
- Funds reported $227M of VistaGen Therapeutics stock for Q1 2021, up 78% quarter-over-quarter.
- 32 funds opened new VistaGen Therapeutics positions in Q1 2021 and 10 closed out, a net change of +22 holders.
- The largest VistaGen Therapeutics buyer in Q1 2021 was NEA Management Company, an estimated $15.4M added.
- The largest VistaGen Therapeutics seller in Q1 2021 was Asymmetry Capital Management, an estimated $4.34M sold.
Based on aggregated 13F filings for Q1 2021.